Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 540

1.

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Minisola S, Marin F, Kendler DL, Geusens P, Zerbini CAF, Russo LA, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Moericke R, Bagur A, Lakatos P, López-Romero P, Body JJ.

Arch Osteoporos. 2019 Jan 18;14(1):10. doi: 10.1007/s11657-019-0561-x.

PMID:
30659410
2.

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.

Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL.

Clin Gastroenterol Hepatol. 2019 Jan 7. pii: S1542-3565(19)30009-6. doi: 10.1016/j.cgh.2018.12.036. [Epub ahead of print]

PMID:
30630103
3.

Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic.

Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL.

Dig Liver Dis. 2018 Dec 3. pii: S1590-8658(18)31232-5. doi: 10.1016/j.dld.2018.11.013. [Epub ahead of print]

PMID:
30591367
4.

Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis-a Systematic Review.

Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL.

Clin Gastroenterol Hepatol. 2018 Dec 21. pii: S1542-3565(18)31397-1. doi: 10.1016/j.cgh.2018.12.021. [Epub ahead of print] Review.

PMID:
30583048
5.

Redox Profiling Reveals Clear Differences between Molecular Patterns of Wound Fluids from Acute and Chronic Wounds.

Bodnár E, Bakondi E, Kovács K, Hegedűs C, Lakatos P, Robaszkiewicz A, Regdon Z, Virág L, Szabó É.

Oxid Med Cell Longev. 2018 Nov 18;2018:5286785. doi: 10.1155/2018/5286785. eCollection 2018.

6.

Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes.

Ilias A, Lovasz BD, Gonczi L, Kurti Z, Vegh Z, Sumegi LD, Golovics PA, Rudas G, Lakatos PL.

J Gastrointestin Liver Dis. 2018 Dec;27(4):391-397. doi: 10.15403/jgld.2014.1121.274.ocm.

7.

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study.

Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, Andersen KW, Andersen V, Kaimakliotis IP, Fumery M, Gower-Rousseau C, Girardin G, Valpiani D, Goldis A, Brinar M, Čuković-Čavka S, Oksanen P, Collin P, Barros L, Magro F, Misra R, Arebi N, Eriksson C, Halfvarson J, Kievit HAL, Pedersen N, Kjeldsen J, Myers S, Sebastian S, Katsanos KH, Christodoulou DK, Midjord J, Nielsen KR, Kiudelis G, Kupcinskas L, Nikulina I, Belousova E, Schwartz D, Odes S, Salupere R, Carmona A, Pineda JR, Vegh Z, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group.

J Gastroenterol Hepatol. 2018 Dec 18. doi: 10.1111/jgh.14563. [Epub ahead of print]

PMID:
30562421
8.

High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.

Chao CY, Al Khoury A, Aruljothy A, Restellini S, Wyse J, Afif W, Bitton A, Lakatos PL, Bessissow T.

Dig Dis Sci. 2018 Nov 16. doi: 10.1007/s10620-018-5358-z. [Epub ahead of print]

PMID:
30446928
9.

Reply to Letter on: "Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis".

Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T.

J Crohns Colitis. 2018 Oct 29. doi: 10.1093/ecco-jcc/jjy176. [Epub ahead of print] No abstract available.

PMID:
30371761
10.

Herpes Zoster Incidence in Inflammatory Bowel Disease Patients: A Population-Based Study.

Côté-Daigneault J, Bessissow T, Nicolae MV, Nie R, Bitton A, Lakatos PL, Brassard P.

Inflamm Bowel Dis. 2018 Oct 5. doi: 10.1093/ibd/izy311. [Epub ahead of print]

PMID:
30295818
11.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group.

J Crohns Colitis. 2018 Oct 5. doi: 10.1093/ecco-jcc/jjy154. [Epub ahead of print]

PMID:
30289522
12.

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.

Bálint A, Rutka M, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Szepes Z, Nagy F, Palatka K, Lovas S, Végh Z, Kürti Z, Csontos Á, Miheller P, Nyári T, Bor R, Milassin Á, Fábián A, Szántó K, Lakatos PL, Molnár T, Farkas K.

Expert Opin Biol Ther. 2018 Nov;18(11):1181-1187. doi: 10.1080/14712598.2018.1530758. Epub 2018 Oct 9.

PMID:
30277084
13.

Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T.

J Crohns Colitis. 2019 Jan 1;13(1):27-38. doi: 10.1093/ecco-jcc/jjy143.

PMID:
30247650
14.

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K.

Qual Life Res. 2019 Jan;28(1):141-152. doi: 10.1007/s11136-018-2003-4. Epub 2018 Sep 17.

PMID:
30225788
15.

Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives.

Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones J, Lakatos PL, Sewitch M, El-Matary W, Melmed G, Nguyen G; QI consensus group; Promoting Access and Care through Centers of Excellence-PACE program).

Inflamm Bowel Dis. 2019 Jan 10;25(2):403-409. doi: 10.1093/ibd/izy259.

PMID:
30169582
16.

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.

Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL.

World J Gastroenterol. 2018 Aug 28;24(32):3567-3582. doi: 10.3748/wjg.v24.i32.3567. Review.

17.

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.

Goncalves J, Magro F, Danese S, Lakatos PL, Ben-Horin S.

Aliment Pharmacol Ther. 2018 Sep;48(5):575-576. doi: 10.1111/apt.14860. No abstract available.

PMID:
30156326
18.

Biosimilars in ulcerative colitis: When and for who?

Ilias A, Gonczi L, Kurti Z, Lakatos PL.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:35-42. doi: 10.1016/j.bpg.2018.05.003. Epub 2018 May 26. Review.

PMID:
30060937
19.

Top-down, contextual entrainment of neuronal oscillations in the auditory thalamocortical circuit.

Barczak A, O'Connell MN, McGinnis T, Ross D, Mowery T, Falchier A, Lakatos P.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7605-E7614. doi: 10.1073/pnas.1714684115. Epub 2018 Jul 23.

20.

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, Kaplan GG, Burisch J, Colombel JF.

Gastroenterology. 2018 Oct;155(4):1079-1089.e3. doi: 10.1053/j.gastro.2018.06.043. Epub 2018 Jun 27.

PMID:
29958857
21.

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Strohl M, Gonczi L, Kurt Z, Bessissow T, Lakatos PL.

World J Gastroenterol. 2018 Jun 14;24(22):2363-2372. doi: 10.3748/wjg.v24.i22.2363. Review.

22.

Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.

Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, Afif W, Lakatos PL, Bitton A, Cocciolillo S, Ghali P, Bessissow T, Sebastiani G.

Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133. doi: 10.1093/ibd/izy200.

PMID:
29889226
23.

Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.

Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, Catarina Cunha-Santos A, Barbas A, Galvão J, Barbosa I, Aires da Silva F, Alcobia A, Cavaco M, Cardoso M, Delgado Alves J, Carey JJ, Dörner T, Eurico Fonseca J, Palmela C, Torres J, Lima Vieira C, Trabuco D, Fiorino G, Strik A, Yavzori M, Rosa I, Correia L, Magro F, D'Haens G, Ben-Horin S, Lakatos PL, Danese S.

Aliment Pharmacol Ther. 2018 Sep;48(5):507-522. doi: 10.1111/apt.14808. Epub 2018 Jun 5.

PMID:
29873091
24.

Impact of genetic influence on serum total- and free 25-hydroxyvitamin-D in humans.

Szili B, Szabó B, Horváth P, Bakos B, Kirschner G, Kósa JP, Toldy E, Putz Z, Lakatos P, Tabák Á, Takács I.

J Steroid Biochem Mol Biol. 2018 Oct;183:62-67. doi: 10.1016/j.jsbmb.2018.05.007. Epub 2018 May 21.

PMID:
29792983
25.

Endoscopic management of Crohn's strictures.

Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G.

World J Gastroenterol. 2018 May 7;24(17):1859-1867. doi: 10.3748/wjg.v24.i17.1859. Review.

26.

Progress with infliximab biosimilars for inflammatory bowel disease.

Kurti Z, Gonczi L, Lakatos PL.

Expert Opin Biol Ther. 2018 Jun;18(6):633-640. doi: 10.1080/14712598.2018.1469620. Epub 2018 Apr 29.

PMID:
29688797
27.

Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.

Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1531-1538. doi: 10.1093/ibd/izy044.

PMID:
29668893
28.

The Spectrum of Thyroid Gland Pathology in Carney Complex: The Importance of Follicular Carcinoma.

Carney JA, Lyssikatos C, Seethala RR, Lakatos P, Perez-Atayde A, Lahner H, Stratakis CA.

Am J Surg Pathol. 2018 May;42(5):587-594. doi: 10.1097/PAS.0000000000000975.

PMID:
29635258
29.

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M.

United European Gastroenterol J. 2018 Mar;6(2):310-321. doi: 10.1177/2050640617708952. Epub 2017 May 8.

30.

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.

Kurti Z, Ilias A, Gonczi L, Vegh Z, Fadgyas-Freyler P, Korponay G, Golovics PA, Lovasz BD, Lakatos PL.

BMC Gastroenterol. 2018 Jan 30;18(1):23. doi: 10.1186/s12876-018-0746-6.

31.

Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.

Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D'Incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-Rousseau C, Chetcuti Zammit S, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-Cavka S, Langholz E, Munkholm P; Epi-IBD group.

Gut. 2018 Jan 23. pii: gutjnl-2017-315568. doi: 10.1136/gutjnl-2017-315568. [Epub ahead of print]

PMID:
29363534
32.

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.

Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A.

J Bone Miner Res. 2018 May;33(5):783-794. doi: 10.1002/jbmr.3384. Epub 2018 Feb 9.

PMID:
29329484
33.

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M.

Sci Rep. 2018 Jan 10;8(1):399. doi: 10.1038/s41598-017-18622-1.

34.

The red deer Cervus elaphus genome CerEla1.0: sequencing, annotating, genes, and chromosomes.

Bana NÁ, Nyiri A, Nagy J, Frank K, Nagy T, Stéger V, Schiller M, Lakatos P, Sugár L, Horn P, Barta E, Orosz L.

Mol Genet Genomics. 2018 Jun;293(3):665-684. doi: 10.1007/s00438-017-1412-3. Epub 2018 Jan 2.

PMID:
29294181
35.

Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.

Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T.

Dig Dis Sci. 2018 May;63(5):1302-1310. doi: 10.1007/s10620-017-4874-6. Epub 2017 Dec 14.

PMID:
29243105
36.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.

Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9. Erratum in: Lancet. 2017 Nov 30;:. Erratum in: Lancet. 2018 Dec 1;392(10162):2352.

PMID:
29129436
37.

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

Gonczi L, Kurti Z, Golovics PA, Lovasz BD, Menyhart O, Seres A, Sumegi LD, Gal A, Ilias A, Janos P, Gecse KB, Bessisow T, Afif W, Bitton A, Vegh Z, Lakatos PL.

Dig Liver Dis. 2018 Jan;50(1):37-41. doi: 10.1016/j.dld.2017.09.137. Epub 2017 Oct 9.

PMID:
29107471
38.

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.

Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):722-731. doi: 10.1210/jc.2017-01471.

PMID:
29099947
39.

Correction: What do we talk about when we talk about rhythm?

Obleser J, Henry MJ, Lakatos P.

PLoS Biol. 2017 Nov 1;15(11):e1002615. doi: 10.1371/journal.pbio.1002615. eCollection 2017 Nov.

40.

Access to biologicals in Crohn's disease in ten European countries.

Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodszky V, Baji P, Crohn's Disease Research Group.

World J Gastroenterol. 2017 Sep 14;23(34):6294-6305. doi: 10.3748/wjg.v23.i34.6294.

41.

Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease.

Restellini S, Kherad O, Bessissow T, Ménard C, Martel M, Taheri Tanjani M, Lakatos PL, Barkun AN.

World J Gastroenterol. 2017 Aug 28;23(32):5994-6002. doi: 10.3748/wjg.v23.i32.5994. Review.

42.

What do we talk about when we talk about rhythm?

Obleser J, Henry MJ, Lakatos P.

PLoS Biol. 2017 Sep 19;15(9):e2002794. doi: 10.1371/journal.pbio.2002794. eCollection 2017 Sep. No abstract available. Erratum in: PLoS Biol. 2017 Nov 1;15(11):e1002615.

43.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.

Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL.

Inflamm Bowel Dis. 2017 Nov;23(11):1908-1915. doi: 10.1097/MIB.0000000000001237.

PMID:
28922253
44.

SIRT1/HERC4 Locus Associated With Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis.

Yang G, Hamadeh IS, Katz J, Riva A, Lakatos P, Balla B, Kosa J, Vaszilko M, Pelliccioni GA, Davis N, Langaee TY, Moreb JS, Gong Y.

J Bone Miner Res. 2018 Jan;33(1):91-98. doi: 10.1002/jbmr.3285. Epub 2017 Oct 16.

45.

Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M.

World J Gastroenterol. 2017 Aug 7;23(29):5412-5421. doi: 10.3748/wjg.v23.i29.5412.

46.

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.

Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.

Expert Opin Biol Ther. 2017 Nov;17(11):1325-1332. doi: 10.1080/14712598.2017.1363885. Epub 2017 Aug 18.

PMID:
28819991
47.

Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.

Lee M, Balla A, Sershen H, Sehatpour P, Lakatos P, Javitt DC.

Neuropsychopharmacology. 2018 Feb;43(3):571-582. doi: 10.1038/npp.2017.176. Epub 2017 Aug 17.

PMID:
28816240
48.

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.

Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL.

BMC Gastroenterol. 2017 Aug 8;17(1):97. doi: 10.1186/s12876-017-0654-1.

49.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A.

Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.

PMID:
28755782
50.

The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study.

Kuenzig ME, Yim J, Coward S, Eksteen B, Seow CH, Barnabe C, Barkema HW, Silverberg MS, Lakatos PL, Beck PL, Fedorak R, Dieleman LA, Madsen K, Panaccione R, Ghosh S, Kaplan GG.

EBioMedicine. 2017 Jul;21:188-196. doi: 10.1016/j.ebiom.2017.06.012. Epub 2017 Jun 16. Review.

Supplemental Content

Loading ...
Support Center